original contributions ADRB1 Polymorphisms and Response to β-Blockade in AASK tion but increased cAMP activity; [11] [12] [13] Arg389 has also been associated with short-term blood pressure-lowering effects in response to metoprolol in several studies. [14] [15] [16] In this analysis, we used the AASK dataset to explore the relationship between ADRB1 Ser49Gly and Arg389Gly variants and blood pressure response to metoprolol. As described in our previous studies, the analysis focused on survival methodology utilizing time to reach a target mean arterial pressure (MAP) of ≤107 mm Hg as the primary end point. 8, 17, 18 
MethODs
Participants and study design. Specific details regarding the AASK protocol and AASK Genetics Study based on 1,094 African-American men with hypertensive nephrosclerosis have been previously published. 4, 8, [17] [18] [19] [20] From this base population, 329 (39.35%) participants were randomized to metoprolol. The AASK trial randomly assigned subjects to one of two MAP groups: a usual MAP group (102-107 mm Hg) or a low MAP group (≤92 mm Hg). However, MAP group was known to both investigators and participants.
Genetics. Two single nonsynonymous ADRB1 polymorphisms were analyzed: Ser49Gly (rs1801252) and Gly389Arg (rs1801253). At 145 base pairs on ADRB1, an A>G substitution results in an amino acid change from Serine to Glycine (Ser49Gly). At 1,165 base pairs, a C>G substitution results in a change from Arginine to Glycine (Arg389Gly). 21 DNA isolation and genotyping has been previously detailed in our other studies. 8, 17, 18 Deviation from Hardy-Weinberg equilibrium was tested using the Pearson goodness of fit (χ 2 ) test statistic. In this dataset, Ser49Gly and Gly389Arg were not in linkage disequilibrium (r 2 = 0.18) as determined by the SAS software expectation maximization algorithm (version 9.1; SAS Institute, Cary, NC).
Statistical analysis.
Analysis was limited to the first year of randomization because progressive renal disease could obscure the potential relationship between genotype and antihypertensive blood pressure response. ADRB1 haplotypes were not used in this analysis because Ser49Gly and Gly389Arg were in low linkage disequilibrium. As described in our previous papers, this analysis focused on the relationship between genotype and the time to reach a target MAP of 107 mm Hg. A target of 107 mm Hg was used because it was the prespecified target for the usual MAP group in the original AASK trial. 4 In order to be considered a treatment success, participants had to have two consecutive MAP readings ≤107 mm Hg with the average of the remaining MAPs within the first year after randomization ≤107 mm Hg.
Descriptive statistics for baseline characteristics were analyzed by ADRB1 genotypes using either the Kruskal-Wallis test or Fisher's exact test. Univariate association between genotype and time to reach a target MAP of 107 mm Hg was analyzed using log-rank test and visualized by Kaplan-Meier curves. Cox proportional hazards models were used for multivariable analysis. Potential covariates considered in multivariable analysis included demographics, body mass index (BMI), renal function, comorbidities and lifestyle factors. The AASK study added other antihypertensive drugs to manage blood pressure using a specific protocol: diuretic → α-adrenergic antagonist → central α-adrenergic agonist. 20 Therefore, a proxy of average number of medications per day could be used to control for the use of these other antihypertensive drugs. However, medications were also highly associated with baseline MAP (P < 0.0001) and goal group (P < 0.0005); therefore, we considered only baseline MAP and goal group in the multivariable model because these two variables are significantly associated with both outcome and genotype.
Cox proportional hazards model was also used to estimate the hazard ratio (HR) of reaching a target MAP of 107 mm Hg and 95% confidence interval (CI) for potential covariates. Variables that appeared to be associated (P < 0.25) with either ADRB1 genotypes or with the main outcome (days to target MAP 107 mm Hg) were added to the multivariable model. The partial likelihood ratio test was used to assess the significance of covariates in the multivariable proportional hazard model. The method of purposeful selection was used for the selection of covariates for the final model. 22 Variables resulting in a 20% change in any estimated coefficient were considered as confounders. All possible two-way interactions were assessed and retained in the final model if it is significant at P < 0.05 by the partial likelihood ratio test. Fractional polynomials were used to assess linearity assumption between the continuous variables and the outcome. 23 The effects of influential observations on estimated parameters were assessed by score residuals 22 and the proportional hazards assumption was assessed using the test by Grambsch and Therneau. 24 P values were not adjusted for multiple comparisons. Statistical analysis was carried out using statistical software R version 2.8.1 (http://www.R-project.org).
Population stratification and specificity control. It has previously been shown in the AASK dataset that population stratification does not contribute to blood pressure response as determined by general analysis of molecular variance. 8, 17, 25 Because ADRB1 is not in the pharmacological pathway of ramipril (an angiotensin-converting enzyme inhibitor) or amlodipine (a calcium channel blocker), participants randomized to these other two study drugs were used as a control for specificity of the effect of variant on phenotype.
ResUlts Genetics
Of the 328 participants randomized to metoprolol, 315 (96%) and 310 (94%) were genotyped at Ser49Gly and Arg389Gly, respectively. Allele frequencies for both polymorphisms were in Hardy-Weinberg equilibrium. However, it is important to note that there were few homozygous Gly49 individuals (N = 16, 4.8%).
study participant characteristics
There were 197 men (60%, mean age 55 years ± 10 years) and 132 women (40%, mean age 54 ± 10 years). Of the 167 original contributions ADRB1 Polymorphisms and Response to β-Blockade in AASK randomized to a usual MAP group, 140 (84%) reached a target MAP of 107 mm Hg. Of the 162 randomized to a low MAP group, 153 (94%) reached a target MAP of 107 mm Hg (results not shown). Ser49Gly was significantly associated with baseline MAP (P < 0.05) and triglycerides (P < 0.01). Participants with Gly389 were older (P < 0.05); those with an Arg389 had higher baseline MAP (P < 0.05) and those with Arg389/Gly389 were more likely to have >1 comorbid disease (P ≤ 0.05, Table 1 ).
Model 1: ser49Gly
Based on initial Kaplan-Meier curve and log-rank test, there did not appear to be significant differences between Ser49Gly variants and the time to reach a target MAP 107 mm Hg (Figure 1) . Cox model estimates with and without influential observations were similar; therefore, final results were based on the inclusion of all observations. Cox regression analysis suggested that baseline MAP (P < 0.001), treatment goal (P < 0.05), and serum potassium (P < 0.001) were associated with blood pressure response to metoprolol ( Table 2) . There was also a significant interaction between Ser49/Gly49 and BMI (P < 0.05); BMI was analyzed as a continuous variable. There was also an interaction between baseline MAP and randomization group (P < 0.01).
Because of the interaction with BMI, HRs for Ser49Gly variants were calculated at different levels of BMI. The hazard rate of reaching a target MAP of 107 mm Hg for subjects with Ser49/Gly49 was not significantly different from subjects with Ser49/Ser49 if the BMI was <39 kg/m 2 (selected HRs shown in Table 3 ). However, the rate of reaching blood pressure control in Ser49/Gly49 individuals (compared to Ser49/Ser49) was reduced by 32% if their BMI was 39 kg/m 2 or more (39 study participants, ~11% if this study population, had a BMI ≥39); the adjusted HR for participants with a BMI of 39 kg/ m 2 was 0.68 (95% CI 0.46-0.99) ( Table 3) . Serum potassium was significantly associated with the time to reach a MAP of 107 mm Hg; for every 1 mmol/l increase in serum potassium, the HR of reaching the target MAP was 1.46 (95% CI 1.24-1.76). Among those randomized to a low MAP group, the HR for a 5 mm Hg increase in baseline MAP was 0.91 (95% CI 0.86-0.96); among those randomized to a usual MAP group, the HR was 0.81 (95% 0.76-0.87). The proportional hazards assumption was satisfied in the final model.
Model 2: Gly389Arg
Kaplan-Meier analysis suggested that Arg389Gly genotypes were associated with blood pressure response to metoprolol (P<0.05; Figure 2 ). Differences between Arg389/Arg389 and Arg389/ Gly389 were not significant (data not shown); therefore, these groups were combined for the multivariable analysis. Cox model estimates with and without influential observations were similar; therefore, final results were based on the inclusion of all observations. The estimated coefficient for ADRB1 Arg389/Arg389 and Arg389/Gly389 was significant (P < 0.05), suggesting that the Arg389 was a predictor of blood pressure response to metoprolol in comparison to Gly389/Gly389 ( Table 4) . Gender (P < 0.05), baseline MAP (P < 0.001) and serum potassium (P < 0.001) were also significant predictors of blood pressure response. An interaction between randomization group and baseline MAP was again observed in Arg389Gly model (P < 0.05).
The rate of reaching a target MAP of 107 mm Hg was less in individuals with Arg389 compared to individuals with Gly389/ Gly389: HR 0.68 (95% CI 0.50-0.93; Table 5 ). In comparison to men, the rate of reaching a target MAP in women was less, HR 0.78 (95% CI 0.60-0.995). Serum potassium was again positively associated with blood pressure response: 1.48 (95% CI 1.26-1.75). For a 5 mm Hg increase in baseline MAP, the HR was 0.92 (95% CI 0.87-0.96) for those randomized to the low MAP group, and 0.84 (95% CI 0.78-0.89) for those randomized to the usual MAP group. The proportional hazards assumption was satisfied in the final model.
specificity control and population stratification
As noted in the Methods section, it has been previously shown in this population that genetic admixture does not contribute to spurious associations between genotype and days to reach a target MAP of 107 mm Hg. 8, 17, 25 Among individuals assigned to ramipril or amlodipine, there were no significant associations between Ser49Gly and Gly389Arg and blood pressure response in this dataset (results not shown).
DisCUssiON
In this study, we had a unique opportunity to analyze randomized clinical trial data to explore the relationship between ADRB1 polymorphisms and time to reach a target MAP of 107 mm Hg with metoprolol among African Americans with early hypertensive nephrosclerosis. Ser49Gly appeared to be a predictor of blood pressure response among those with a BMI of 39 or more; the rate of reaching an MAP of 107 mm Hg was reduced by 32% for obese Ser49/Gly49 individuals (compared to Ser49/Ser49). Gly389Arg was also associated with blood pressure response to metoprolol. The rate of reaching an MAP of 107 mm Hg among Arg389 carriers was also 32% lower in comparison to Gly389/Gly389 carriers.
Gly49ser and blood pressure response to metoprolol
In vitro studies have shown differential agonist-promoted desensitization and cAMP levels by Gly49Ser genotypes, with Gly49 exhibiting greater agonist-promoted downregulation and higher cAMP levels in comparison to Ser49. 9, 10 Homozygous Ser49/Ser49 has also been associated with larger decrease in systolic blood pressure compared to Ser49/Gly49 in a Chinese population. 16 In our study, Ser49/Gly49 individuals were less responsive to metoprolol in comparison to Ser49/ Ser49 but only among obese participants (BMI ≥39), suggesting that BMI is an effect modifier with respect to the relationship between Ser49Gly variants and blood pressure response to metoprolol. While Ser49Gly was not significantly associated with BMI in our study population, other studies have found the Gly49 variant to be associated with a higher BMI in patients with type II diabetes and associated with increased long-term weight-gain in women. 26, 27 Genetically engineered mice with an overexpression of ADRB1 in adipose tissue also have increased lipolysis and a decreased propensity for obesity. 28 In vitro studies also reveal that larger fat cells exhibit increased β-adrenoceptor activity. 29 Factors associated with obesity such as hormone levels, nutrition and thyroid disorders may also influence the expression and function of β-adrenoceptors. 30 Therefore, while decreased activity of the Gly49 variant may contribute to increased body fat, obesity may also alter the pharmacokinetics of metoprolol as well. β-Blockers such as metoprolol have been shown to preferentially diffuse into lean tissue 31 and obese patients have been shown to be more responsive to metoprolol. 32 In addition, the altered physiology of morbid obesity may affect the receptor activity or expression or antagonist disposition eliciting a differential metoprolol response according to Ser49Gly genotype. Whether obesity is an effect modifier of the relationship between Ser49Gly genotypes and blood pressure response to metoprolol, as observed here, remains to be clarified.
Gly389Arg and blood pressure response to metoprolol
In comparison to the wild-type Gly389, the Arg389 is a gainof-function variant with higher basal adenylyl cyclase activity 12 and less agonist-promoted desensitization, equivalent to nondesensitized Gly389 activity. 13 Previous studies have also suggested that Arg389 individuals have significantly greater change in blood pressure in response to treatment with a β-blocker, perhaps because of higher starting baseline blood pressures or perhaps because of better short-term response to β-blockade. [14] [15] [16] 33 In contrast, our study found that Arg389 individuals were less likely to reach a target MAP when blood pressure was analyzed over a longer-term 1-year period, suggesting that the effectiveness of β-blockers with Arg389 may be a challenge due to higher basal ADRB1 activity (i.e., less agonist-promoted desensitization and higher cAMP levels). In addition, Gly389Arg was also not associated with short-term response to metoprolol in this patient population (results not shown).
Other predictors of blood pressure response
As expected, study participants with a higher baseline MAP were less responsive to metoprolol. The effect of baseline MAP was more pronounced among those randomized to a usual MAP group (significant interaction term between treatment goal × baseline MAP), most likely as a result of more aggressive antihypertensive drug management in the low MAP group. In the Arg389Gly model, women had a decreased rate of reaching a target MAP in comparison to men (HR 0.78, 95% CI 0.60-0.995). Although gender was not significant in the Ser49Gly model, the effect of gender on blood pressure response was of a similar magnitude as observed in the Arg389Gly model (HR 0.79, 95% CI 0.56-1.07; results not shown). Although we did not find evidence for an interaction between ADRB1 genotypes and gender, ADRB1 densities in murine pulmonary tissue have been shown to decrease ~40% in males but remain stable in females in response to stress. 34 Men in a "physiologically stressed" milieu may be able to compensate by downregulating ADRB1 receptor density.
Finally, serum potassium levels were positively associated with blood pressure response, similar to what has been observed in several other epidemiological studies. In a metaanalysis of 27 randomized trials examining potassium supplementation and blood pressure response, an increase in Limitations of this study have been previously published and are also briefly mentioned here. 17 While most prior studies with ADBR1 polymorphisms focused on short-term blood pressure measurements before and after treatment with metoprolol, [14] [15] [16] this study analyzed the time to reach target MAP related to ADBR1 genotypes using similar survival methodology using meticulously measured blood pressure from a randomized trial as previously described by Bhatnagar et al. 17 This approach potentially allows a more comprehensive sampling of blood pressure data over 1 year and may represent a more clinically relevant phenotype. Although this is a retrospective analysis, our study sample was representative of the original AASK cohort (not differing in baseline age, sex, blood pressure, or renal function). It is unclear how the effect of loss to follow-up or death may bias these results. By design of the original cohort, the results are not readily applicable to other ethnicities or subjects without hypertensive nephrosclerosis. This study was not sufficiently powered to detect smaller changes in blood pressure or effects on rare variants such as ADRB1 Gly49Gly. The analysis was also limited to the first year of randomization because of the effects of declining renal function on blood pressure. While the average medications per day could be used as a proxy measure for the additional antihypertensive medications, this was also highly correlated to baseline MAP; thus, only one of these variables (baseline MAP) was used in the final Cox model. In summary, this study applied survival methodology to assess the effects of ADRB1 polymorphisms on blood pressure response over a 1-year time period using randomized trial data based on African Americans with early hypertensive nephrosclerosis. Individuals with Ser49/Gly49 (in comparison to Ser49/Ser49) were less likely to respond to metoprolol but only among study participants with a BMI ≥39 kg/m 2 , a novel finding suggesting effect modification. In contrast to other studies focused on short-term blood pressure response, study participants with Arg389 were less responsive to metoprolol when blood pressure was analyzed over a 1-year time period. While the reasons for this observation are speculative at this point, differential agonist-promoted desensitization and the influence of effect modifiers such as obesity, gender differences and compensatory physiological responses to stress may be important considerations, warranting further clinical investigation in different patient populations.
